Larry Ellison cancels plan to sell Oracle stock worth up to $7.5B

Oracle co-founder and Executive Chair Larry Ellison canceled a planned sale of up to 50 million shares, worth about $7.5 billion at Friday's close, and the company said no shares were sold under the plan. The cancellation follows a volatile week in which Oracle beat quarterly estimates and reported a smaller-than-expected cash burn, but analysts cautioned that free-cash-flow recovery remains distant amid debt-funded capital spending. Oracle shares remain down nearly 23% year to date, while planned restructuring and job cuts are expected to add roughly $700 million in costs.

Analysis

The canceled sale plan removes a modest near-term technical overhang, but it is not an operating catalyst: the affected block is only a low-single-digit percentage of shares outstanding and the absence of a stated rationale limits its signaling value. A relief rally driven by perceived insider confidence is therefore vulnerable if investors continue to discount Oracle on the duration of negative or weak free-cash-flow conversion. The key valuation question is whether AI-infrastructure revenue can scale before depreciation, interest expense, and working-capital needs force another reset in cash-flow expectations.

Over the next 1-3 months, sell-side estimate revisions to FY27 free cash flow, net-debt trajectory, and backlog-to-revenue conversion matter far more than the insider headline. Restructuring raises the risk that reported EPS benefits from cost actions obscure a weaker cash outcome; investors should separate recurring opex savings from cash severance, lease, and implementation charges. The most direct second-order beneficiaries of sustained Oracle buildout remain AI-data-center supply-chain names such as NVDA, AVGO, VRT and CEG, although their upside depends on Oracle's orders being incremental rather than capacity shifted from other hyperscalers.

Contrarianly, the market may be too focused on aggregate capex if management can demonstrate that contracted cloud demand produces a visible inflection in operating cash flow within two quarters. Conversely, a further stock rebound without upward revisions to forward FCF would be an attractive fade: Oracle's multiple cannot sustainably re-rate on backlog alone while capital intensity remains elevated. The thesis is falsified by two consecutive quarters of improving operating cash flow and capex discipline, paired with maintained cloud growth and no material increase in net leverage.

Key Decisions for Investors

• Do not chase a near-term ORCL rally solely on the canceled sale plan; treat it as a technical-overhang removal rather than a fundamental buy signal. Reassess after the next earnings release only if management provides quarterly capex, operating-cash-flow, and debt guidance.
• On a 5-10% ORCL rebound without positive revisions to consensus next-twelve-month free cash flow, initiate a tactical short ORCL versus long MSFT in equal dollar amounts for a 1-3 month horizon. The relative trade isolates Oracle's weaker cash-conversion risk; cover if Oracle guides to a clear two-quarter FCF inflection or if the pair moves 8% against entry.
• For existing ORCL longs, use an earnings-dated put spread rather than outright sales if maintaining strategic exposure: buy a near-the-money put and sell a 10-15% lower strike put. The structure targets another cash-flow or capex disappointment while limiting premium outlay; avoid implementation until implied volatility is checked against its one-year range.
• Maintain watch-list exposure to VRT and CEG rather than adding on the Oracle headline. Add only if Oracle's next disclosure confirms sustained data-center deployment and the companies report order growth or contracted load that is independently attributable to incremental AI capacity.